NTRK fusion in soft tissue sarcomas harboring MDM2/CDK4 amplification: three case reports [0.03%]
软组织肉瘤中MDM2/CDK4扩增患者的NTRK融合基因：3例报告
M Brahmi,A Dufresne,B Verret et al.
M Brahmi et al.
Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs [0.03%]
新一代ALK酪氨酸激酶抑制剂治疗后患者的劳拉替尼血脑屏障穿透力及其对ALK阳性非小细胞肺癌的疗效研究
E Felip,A T Shaw,A Bearz et al.
E Felip et al.
Background: Lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI), has substantial activity against ALK-positive non-small-cell lung cancer (NSCLC). This ...
Advances in cancer research dissemination through the pandemic and beyond [0.03%]
新冠疫情之下及之后癌症研究的传播进展
A Desai,I M Subbiah,V Subbiah
A Desai
European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer [0.03%]
2021年欧洲癌症死亡率预测研究：聚焦胰腺癌和女性肺癌
G Carioli,M Malvezzi,P Bertuccio et al.
G Carioli et al.
Background: We predicted cancer mortality statistics for 2021 for the European Union (EU) and its five most populous countries plus the UK. We also focused on pancreatic cancer and female lung cancer. ...
Predictions of cancer mortality in Europe in 2021: room for hope in the shadow of COVID-19? [0.03%]
欧洲2021年癌症死亡预测研究：在COVID-19的影响下仍有希望吗？
J M Martin-Moreno,S Lessof
J M Martin-Moreno
Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer [0.03%]
患者主导的发现及塞尔帕替尼治疗RET融合阳性肺癌获得性耐药机制NTRK3重排的临床后验证
V Subbiah,T Shen,M Tetzlaff et al.
V Subbiah et al.
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy [0.03%]
化疗联合内分泌治疗前预测激素受体阳性的人类表皮生长因子受体2阴性乳腺癌（HR+/HER2-）II-III期患者的内分泌治疗敏感性
L Du,C Yau,L Brown-Swigart et al.
L Du et al.
Background: We proposed that a test for sensitivity to the adjuvant endocrine therapy component of treatment for patients with stage II-III breast cancer (SET2,3) should measure transcription related to estrogen and proge...
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma [0.03%]
FAST：一项关于扎鲁司特单抗（IMAB362）联合EOX与单纯EOX一线治疗CLDN18.2阳性晚期胃及胃食管交界腺癌的Ⅱ期随机研究
U Sahin,Ö Türeci,G Manikhas et al.
U Sahin et al.
Background: Claudin 18.2 (CLDN18.2) is contained within normal gastric mucosa epithelial tight junctions; upon malignant transformation, CLDN18.2 epitopes become exposed. Zolbetuximab, a chimeric monoclonal antibody, medi...
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy [0.03%]
胃食管癌检查点抑制剂：剖析异质性以更好地理解其在一线和辅助治疗中的作用
E C Smyth,V Gambardella,A Cervantes et al.
E C Smyth et al.
Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are responsible for >1 million deaths annually globally. Until now, patients with metastatic GEA and ESCC could anticipate survival of
Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient [0.03%]
纵向无细胞DNA全外显子测序用于追踪肿瘤和免疫逃逸的协同进化动力学：来自单一患者的数据
R K Hastings,M R Openshaw,M Vazquez et al.
R K Hastings et al.